Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CHKA | P35790 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.36 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.33 |
| ▸ | GABRP | O00591 | 1/20 | 0.33 |
| ▸ | GABRD | O14764 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azepane SCHEMBL27420992 | 1.00 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2CXCR4CA2CHKA | |
| Pyrrolidine SCHEMBL1202575 | 0.97 | — | — | |
| Azetidine SCHEMBL17460271 | 0.89 | — | — | |
| Piperidine SCHEMBL4603677 | 0.88 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2CXCR4CA2CHKA | |
| Azepane SCHEMBL9671876 | 0.88 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2CXCR4CA2CHKA | |
| Pyrrolidine SCHEMBL3402069 | 0.84 | — | — | |
| Azepane SCHEMBL714889 | 0.83 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2CXCR4CA2CHKA | |
| Piperidine SCHEMBL720107 | 0.83 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2CXCR4CA2CHKA | |
| Piperidine SCHEMBL4577836 | 0.83 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2CXCR4CA2CHKA | |
| Piperazine SCHEMBL3987157 | 0.82 | HIF1A (0.50) | ALDH1A1SMN1; SMN2CXCR4CA2CHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117164596-A | Coumarin compound and preparation method and application thereof | 新疆农业大学 | 2023-12-05 | — | — | CN | disclosed |
| US-9981972-B2 | N-hydroxy bicyclic hydantoin carbamates as tools for identification of serine hydrolase targets | ABIDE THERAPEUTICS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20170183353-A1 | N-HYDROXY BICYCLIC HYDANTOIN CARBAMATES AS TOOLS FOR INDETIFICATION OF SERINE HYDROLASE TARGETS | H. LUNDBECK A/S (DK) | 2017-06-29 | — | — | US | disclosed |
| WO-2015179563-A2 | N-HYDROXY BICYCLIC HYDANTOIN CARBAMATES AS TOOLS FOR IDENTIFICATION OF SERINE HYDROLASE TARGETS | ABIDE THERAPEUTICS, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
| US-8173648-B2 | 1,2,3,4-tetrahydroisoquinoline derivatives, preparation process therefor and pharmaceutical composition containing the same | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2012-05-08 | — | — | US | disclosed |
| US-20100016309-A1 | 1,2,3,4-Tetrahydroisoquinoline Derivatives, Preparation Process therefor and Pharmaceutical Composition Containing the Same | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2010-01-21 | — | — | US | disclosed |
| CN-101547926-A | 4, 5, 6, 7-tetrahydro-thieno [3, 2-c] pyridine derivatives as H3 modulators | HOFFMANN LA ROCHE (CH) | 2009-09-30 | — | — | CN | disclosed |
| CN-101541810-A | 4,5,6, 7-tetrahydro-thieno [2, 3-c ] pyridines as H3 modulators | HOFFMANN LA ROCHE (CH) | 2009-09-23 | — | — | CN | disclosed |
| CN-100486973-C | Novel benzodioxoles | HOFFMANN LA ROCHE (CH) | 2009-05-13 | — | — | CN | disclosed |
| US-7354922-B2 | Bridged ring NK1 antagonists | SCHERING CORPORATION (US) | 2008-04-08 | — | — | US | disclosed |
| US-20030236267-A1 | Benzimidazole derivatives | MSD K.K. (JP) | 2003-12-25 | — | — | US | disclosed |
| WO-2002085866-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2002-10-31 | — | — | WO | disclosed |
| US-5869480-A | ALLEVIATING MEMORY DYSFUNCTION CHARACTERIZED BY CHOLINERGIC DEFICIT | HOECHST MARION ROUSSEL INC. (US) | 1999-02-09 | — | — | US | disclosed |
| US-5866565-A | ALZHEIMER'S DISORDERS | HOECHST MARION ROUSSEL INC. (US) | 1999-02-02 | — | — | US | disclosed |
| US-5821239-A | USEFUL FOR TREATING ALZHEIMER'S DISEASE CAUSED BY CHOLINERGIC DEFICIT | FROMMER LAWRENCE & HUAG LLP (US) | 1998-10-13 | — | — | US | disclosed |
| EP-0477903-B1 | Substituted-4-amino-3-pyridinols, a process for their preparation and their use as medicaments | HOECHST ROUSSEL PHARMA (US) | 1996-04-03 | — | — | EP | disclosed |
| EP-0477903-A2 | Substituted-4-amino-3-pyridinols, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-04-01 | — | — | EP | disclosed |
| EP-0147909-B1 | ARYLOXY-N-(AMINOALKYL)-1-PYRROLIDINE AND PIPERIDINE CARBOXAMIDES AND CARBOTHIOAMIDES HAVING ANTIARRHYTHMIC ACTIVITY | A.H. ROBINS COMPANY, INCORPORATED (US) | 1989-12-06 | — | — | EP | disclosed |
| US-4547514-A | Aryloxy-N-(aminoalkyl)-1-pyrrolidine and piperidine carboxamides and carbothioamides having antiarrhythmic activity | A. H. ROBINS COMPANY, INCORPORATED (US) | 1985-10-15 | — | — | US | disclosed |
| EP-0147909-A1 | Aryloxy-N-(aminoalkyl)-1-pyrrolidine and piperidine carboxamides and carbothioamides having antiarrhythmic activity | A.H. ROBINS COMPANY, INCORPORATED (US) | 1985-07-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236267-A1 | Benzimidazole derivatives | OPRL1, GPR119, NPBWR1 | ALDH1A1 1636/4885SMN1; SMN2 2200/4885CXCR4 568/4885 |
| US-20100016309-A1 | 1,2,3,4-Tetrahydroisoquinoline Derivatives, Preparation Process therefor and Pharmaceutical Composition Containing the Same | APP, BACE1, PSEN1 | ALDH1A1 881/4885SMN1; SMN2 2712/4885CXCR4 1097/4885 |
| US-20170183353-A1 | N-HYDROXY BICYCLIC HYDANTOIN CARBAMATES AS TOOLS FOR INDETIFICATION OF SERINE HYDROLASE TARGETS | HPN, BCHE, PRSS1 | ALDH1A1 1289/4885SMN1; SMN2 3880/4885CXCR4 3243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.